{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T12:39:33Z","timestamp":1779367173371,"version":"3.53.0"},"reference-count":105,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2019,4,12]],"date-time":"2019-04-12T00:00:00Z","timestamp":1555027200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010109","name":"Medical University of Graz","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100010109","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s00508-018-1425-x","type":"journal-article","created":{"date-parts":[[2019,4,12]],"date-time":"2019-04-12T08:03:57Z","timestamp":1555056237000},"page":"151-163","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Diabetische Nierenerkrankung (Update 2019)","Diabetic kidney disease (Update 2019)"],"prefix":"10.1007","volume":"131","author":[{"given":"Harald","family":"Sourij","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Edlinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedrich C.","family":"Prischl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Auinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Kaser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Horn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Paulweber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Kautzky-Willer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"S\u00e4emann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf","family":"Prager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Clodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guntram","family":"Schernthaner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gert","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Oberbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander R.","family":"Rosenkranz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,12]]},"reference":[{"key":"1425_CR1","volume-title":"Austrian dialysis and transplant registry","author":"R Kramar","year":"2016","unstructured":"Kramar R. Austrian Dialysis and Transplant Registry. Annual report 2017. Accessible via \n                    https:\/\/www.nephro.at\n                    \n                   (accessed 8th December 2018)"},{"issue":"11","key":"1425_CR2","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1093\/ndt\/gfv113","volume":"30","author":"FC Prischl","year":"2015","unstructured":"Prischl FC, Auinger M, Saemann M, et al. Diabetes-related end-stage renal disease in Austria 1965\u20132013. Nephrol Dial Transplant. 2015;30(11):1920\u20137.","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"1425_CR3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2337\/dc13-2112","volume":"37","author":"DM Nathan","year":"2014","unstructured":"Nathan DM, Group DER. The diabetes control and complications trial\/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care. 2014;37(1):9\u201316.","journal-title":"Diabetes Care"},{"issue":"10","key":"1425_CR4","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1681\/ASN.2013091004","volume":"25","author":"IH Boer de","year":"2014","unstructured":"de Boer IH, Afkarian M, Rue TC, et\u00a0al. Renal outcomes in patients with type 1 diabetes and macroalbuminuria. J\u00a0Am Soc Nephrol. 2014;25(10):2342\u201350.","journal-title":"J Am Soc Nephrol"},{"issue":"12","key":"1425_CR5","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner BM, Cooper ME, de Zeeuw D, et\u00a0al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N\u00a0Engl J Med. 2001;345(12):861\u20139.","journal-title":"N Engl J Med"},{"issue":"9200","key":"1425_CR6","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(99)12323-7","volume":"355","author":"Heart Outcomes Prevention Evaluation Study Investigators","year":"2000","unstructured":"Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355(9200):253\u20139.","journal-title":"Lancet"},{"issue":"Suppl 4","key":"1425_CR7","doi-asserted-by":"crossref","first-page":"iv113","DOI":"10.1093\/ndt\/gfv073","volume":"30","author":"A Kainz","year":"2015","unstructured":"Kainz A, Hronsky M, Stel VS, et\u00a0al. Prediction of prevalence of chronic kidney disease in diabetic patients in countries of the European Union up to 2025. Nephrol Dial Transplant. 2015;30(Suppl 4):iv113\u2013iv8.","journal-title":"Nephrol Dial Transplant"},{"issue":"12","key":"1425_CR8","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.2215\/CJN.03700417","volume":"12","author":"LR Zelnick","year":"2017","unstructured":"Zelnick LR, Weiss NS, Kestenbaum BR, et\u00a0al. Diabetes and CKD in the United States Population, 2009\u20132014. Clin J Am Soc Nephrol. 2017;12(12):1984\u201390.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10","key":"1425_CR9","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1056\/NEJMoa1007994","volume":"364","author":"H Haller","year":"2011","unstructured":"Haller H, Ito S, Izzo JL Jr., et\u00a0al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N\u00a0Engl J Med. 2011;364(10):907\u201317.","journal-title":"N Engl J Med"},{"issue":"19","key":"1425_CR10","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa042167","volume":"351","author":"P Ruggenenti","year":"2004","unstructured":"Ruggenenti P, Fassi A, Ilieva AP, et\u00a0al. Preventing microalbuminuria in type 2 diabetes. N\u00a0Engl J Med. 2004;351(19):1941\u201351.","journal-title":"N Engl J Med"},{"issue":"2","key":"1425_CR11","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1053\/j.ajkd.2004.10.019","volume":"45","author":"RC Atkins","year":"2005","unstructured":"Atkins RC, Briganti EM, Lewis JB, et\u00a0al. Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis. 2005;45(2):281\u20137.","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"1425_CR12","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.2337\/dc06-1998","volume":"30","author":"H Makino","year":"2007","unstructured":"Makino H, Haneda M, Babazono T, et\u00a0al. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care. 2007;30(6):1577\u20138.","journal-title":"Diabetes Care"},{"issue":"1","key":"1425_CR13","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1046\/j.1523-1755.2003.00712.x","volume":"63","author":"AI Adler","year":"2003","unstructured":"Adler AI, Stevens RJ, Manley SE, et\u00a0al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003;63(1):225\u201332.","journal-title":"Kidney Int"},{"issue":"9854","key":"1425_CR14","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/S0140-6736(12)61350-6","volume":"380","author":"CS Fox","year":"2012","unstructured":"Fox CS, Matsushita K, Woodward M, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a\u00a0meta-analysis. Lancet. 2012;380(9854):1662\u201373.","journal-title":"Lancet"},{"key":"1425_CR15","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1093\/ajcp\/38.3.270","volume":"38","author":"P Kimmelstiel","year":"1962","unstructured":"Kimmelstiel P, Kim OJ, Beres J. Studies on renal biopsy specimens, with the aid of the electron microscope. I. Glomeruli in diabetes. Am J Clin Pathol. 1962;38:270\u20139.","journal-title":"Am J Clin Pathol"},{"issue":"1","key":"1425_CR16","first-page":"83","volume":"12","author":"P Kimmelstiel","year":"1936","unstructured":"Kimmelstiel P, Wilson C. Intercapillary Lesions in the Glomeruli of the Kidney. Am J Pathol. 1936;12(1):83\u201398.7.","journal-title":"Am J Pathol"},{"issue":"Suppl 2","key":"1425_CR17","doi-asserted-by":"crossref","first-page":"64","DOI":"10.2337\/diab.32.2.S64","volume":"32","author":"CE Mogensen","year":"1983","unstructured":"Mogensen CE, Christensen CK, Vittinghus E. The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy. Diabetes. 1983;32(Suppl 2):64\u201378.","journal-title":"Diabetes"},{"issue":"4","key":"1425_CR18","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1172\/JCI111523","volume":"74","author":"SM Mauer","year":"1984","unstructured":"Mauer SM, Steffes MW, Ellis EN, Sutherland DE, Brown DM, Goetz FC. Structural-functional relationships in diabetic nephropathy. J\u00a0Clin Invest. 1984;74(4):1143\u201355.","journal-title":"J Clin Invest"},{"issue":"Suppl 4","key":"1425_CR19","first-page":"958","volume":"5","author":"JM Steinke","year":"2008","unstructured":"Steinke JM, Mauer M, International Diabetic Nephropathy Study G. Lessons learned from studies of the natural history of diabetic nephropathy in young type 1 diabetic patients. Pediatr Endocrinol Rev. 2008;5(Suppl 4):958\u201363.","journal-title":"Pediatr Endocrinol Rev"},{"issue":"Suppl 2","key":"1425_CR20","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s00508-012-0262-6","volume":"124","author":"M Auinger","year":"2012","unstructured":"Auinger M, Edlinger R, Prischl F, et\u00a0al. Diabetic nephropathy\u2014update 2012. Wien Klin Wochenschr. 2012;124(Suppl 2):42\u20139.","journal-title":"Wien Klin Wochenschr"},{"issue":"24","key":"1425_CR21","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.1001\/jama.289.24.3273","volume":"289","author":"HJ Kramer","year":"2003","unstructured":"Kramer HJ, Nguyen QD, Curhan G, Hsu CY. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA. 2003;289(24):3273\u20137.","journal-title":"JAMA"},{"issue":"6","key":"1425_CR22","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.2337\/db05-1620","volume":"55","author":"R Retnakaran","year":"2006","unstructured":"Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR, Group US. Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes. 2006;55(6):1832\u20139.","journal-title":"Diabetes"},{"key":"1425_CR23","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1471-2369-14-46","volume":"14","author":"A Rodriguez-Poncelas","year":"2013","unstructured":"Rodriguez-Poncelas A, Garre-Olmo J, Franch-Nadal J, et al. Prevalence of chronic kidney disease in patients with type 2 diabetes in Spain: PERCEDIME2 study. Bmc Nephrol. 2013;14:46.","journal-title":"Bmc Nephrol"},{"issue":"8","key":"1425_CR24","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.2337\/dc08-2186","volume":"32","author":"MC Thomas","year":"2009","unstructured":"Thomas MC, Macisaac RJ, Jerums G, et al. Nonalbuminuric renal impairment in type 2 diabetic patients and in the general population (national evaluation of the frequency of renal impairment cO-existing with NIDDM [NEFRON] 11). Diabetes Care. 2009;32(8):1497\u2013502.","journal-title":"Diabetes Care"},{"issue":"9739","key":"1425_CR25","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0140-6736(10)60576-4","volume":"376","author":"F Ismail-Beigi","year":"2010","unstructured":"Ismail-Beigi F, Craven T, Banerji MA, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet. 2010;376(9739):419\u201330.","journal-title":"Lancet"},{"issue":"6","key":"1425_CR26","doi-asserted-by":"crossref","first-page":"954","DOI":"10.2337\/dc15-0184","volume":"38","author":"AS Krolewski","year":"2015","unstructured":"Krolewski AS. Progressive renal decline: the new paradigm of diabetic nephropathy in type 1 diabetes. Diabetes Care. 2015;38(6):954\u201362.","journal-title":"Diabetes Care"},{"issue":"2 Suppl 2","key":"1425_CR27","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1053\/j.ajkd.2013.10.048","volume":"63","author":"RJ Macisaac","year":"2014","unstructured":"Macisaac RJ, Ekinci EI, Jerums G. Markers of and risk factors for the development and progression of diabetic kidney disease. Am J Kidney Dis. 2014;63(2 Suppl 2):S39\u2013S62.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"1425_CR28","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/ki.2014.128","volume":"87","author":"ME Molitch","year":"2015","unstructured":"Molitch ME, Adler AI, Flyvbjerg A, et\u00a0al. Diabetic kidney disease: a\u00a0clinical update from kidney disease: improving global outcomes. Kidney Int. 2015;87(1):20\u201330.","journal-title":"Kidney Int"},{"issue":"4","key":"1425_CR29","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1053\/j.ajkd.2014.08.001","volume":"64","author":"KR Tuttle","year":"2014","unstructured":"Tuttle KR, Bakris GL, Bilous RW, et\u00a0al. Diabetic kidney disease: a\u00a0report from an ADA Consensus Conference. Am J Kidney Dis. 2014;64(4):510\u201333.","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"1425_CR30","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1007\/s001250050616","volume":"39","author":"P Fioretto","year":"1996","unstructured":"Fioretto P, Mauer M, Brocco E, et\u00a0al. Patterns of renal injury in NIDDM patients with microalbuminuria. Diabetologia. 1996;39(12):1569\u201376.","journal-title":"Diabetologia"},{"issue":"4","key":"1425_CR31","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1681\/ASN.2010010010","volume":"21","author":"TW Tervaert","year":"2010","unstructured":"Tervaert TW, Mooyaart AL, Amann K, et\u00a0al. Pathologic classification of diabetic nephropathy. J\u00a0Am Soc Nephrol. 2010;21(4):556\u201363.","journal-title":"J Am Soc Nephrol"},{"issue":"2 Suppl 2","key":"1425_CR32","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1053\/j.ajkd.2013.10.050","volume":"63","author":"RC Stanton","year":"2014","unstructured":"Stanton RC. Clinical challenges in diagnosis and management of diabetic kidney disease. Am J Kidney Dis. 2014;63(2 Suppl 2):S3\u2013S21.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"1425_CR33","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1038\/kisup.2012.73","volume":"3","author":"Group KDIGOKCW","year":"2013","unstructured":"Group KDIGOKCW. 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2013;3(1):S1\u2013S150.","journal-title":"Kidney Int"},{"issue":"6","key":"1425_CR34","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","volume":"130","author":"AS Levey","year":"1999","unstructured":"Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a\u00a0new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130(6):461\u201370.","journal-title":"Ann Intern Med"},{"issue":"4","key":"1425_CR35","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1373\/clinchem.2006.077180","volume":"53","author":"AS Levey","year":"2007","unstructured":"Levey AS, Coresh J, Greene T, et\u00a0al. Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem. 2007;53(4):766\u201372.","journal-title":"Clin Chem"},{"issue":"9","key":"1425_CR36","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, et\u00a0al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604\u201312.","journal-title":"Ann Intern Med"},{"issue":"18","key":"1425_CR37","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1001\/jama.2012.4623","volume":"307","author":"K Kalantar-Zadeh","year":"2012","unstructured":"Kalantar-Zadeh K, Amin AN. Toward more accurate detection and risk stratification of chronic kidney disease. JAMA. 2012;307(18):1976\u20137.","journal-title":"JAMA"},{"issue":"4","key":"1425_CR38","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1053\/j.ajkd.2009.12.011","volume":"55","author":"SL White","year":"2010","unstructured":"White SL, Polkinghorne KR, Atkins RC, Chadban SJ. Comparison of the prevalence and mortality risk of CKD in Australia using the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) Study GFR estimating equations: the AusDiab (Australian Diabetes, Obesity and Lifestyle) Study. Am J Kidney Dis. 2010;55(4):660\u201370.","journal-title":"Am J Kidney Dis"},{"key":"1425_CR39","doi-asserted-by":"crossref","first-page":"g4507","DOI":"10.1136\/bmj.g4507","volume":"349","author":"S Carville","year":"2014","unstructured":"Carville S, Wonderling D, Stevens P, Guideline Development G. Early identification and management of chronic kidney disease in adults: summary of updated NICE guidance. BMJ. 2014;349:g4507.","journal-title":"BMJ"},{"issue":"Suppl 1","key":"1425_CR40","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.2337\/dc18-S010","volume":"41","author":"A American Diabetes","year":"2018","unstructured":"American Diabetes A. 10. Microvascular complications and foot care: standards of medical care in diabetes-2018. Diabetes Care. 2018;41(Suppl 1):S105\u2013S18.","journal-title":"Diabetes Care"},{"issue":"3","key":"1425_CR41","doi-asserted-by":"crossref","first-page":"703","DOI":"10.2337\/dc10-1723","volume":"34","author":"EI Ekinci","year":"2011","unstructured":"Ekinci EI, Clarke S, Thomas MC, et\u00a0al. Dietary salt intake and mortality in patients with type 2 diabetes. Diabetes Care. 2011;34(3):703\u20139.","journal-title":"Diabetes Care"},{"issue":"4","key":"1425_CR42","doi-asserted-by":"crossref","first-page":"861","DOI":"10.2337\/dc10-1722","volume":"34","author":"MC Thomas","year":"2011","unstructured":"Thomas MC, Moran J, Forsblom C, et al. The association between dietary sodium intake, ESRD, and all-cause mortality in patients with type 1 diabetes. Diabetes Care. 2011;34(4):861\u20136.","journal-title":"Diabetes Care"},{"issue":"14","key":"1425_CR43","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJMoa1200303","volume":"368","author":"R Estruch","year":"2013","unstructured":"Estruch R, Ros E, Salas-Salvado J, et al. Primary prevention of cardiovascular disease with a\u00a0Mediterranean diet. N\u00a0Engl J Med. 2013;368(14):1279\u201390.","journal-title":"N Engl J Med"},{"issue":"2","key":"1425_CR44","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/1047-2797(94)00055-X","volume":"5","author":"FM Sacks","year":"1995","unstructured":"Sacks FM, Obarzanek E, Windhauser MM, et al. Rationale and design of the Dietary Approaches to Stop Hypertension trial (DASH). A multicenter controlled-feeding study of dietary patterns to lower blood pressure. Ann Epidemiol. 1995;5(2):108\u201318.","journal-title":"Ann Epidemiol"},{"issue":"4","key":"1425_CR45","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S2213-8587(17)30061-X","volume":"5","author":"LMS Carlsson","year":"2017","unstructured":"Carlsson LMS, Sjoholm K, Karlsson C, et al. Long-term incidence of microvascular disease after bariatric surgery or usual care in patients with obesity, stratified by baseline glycaemic status: a\u00a0post-hoc analysis of participants from the Swedish Obese Subjects study. Lancet Diabetes Endocrinol. 2017;5(4):271\u20139.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9844","key":"1425_CR46","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0140-6736(12)60572-8","volume":"380","author":"M Tonelli","year":"2012","unstructured":"Tonelli M, Muntner P, Lloyd A, et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a\u00a0population-level cohort study. Lancet. 2012;380(9844):807\u201314.","journal-title":"Lancet"},{"issue":"2","key":"1425_CR47","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1681\/ASN.2012070718","volume":"24","author":"M Afkarian","year":"2013","unstructured":"Afkarian M, Sachs MC, Kestenbaum B, et\u00a0al. Kidney disease and increased mortality risk in type 2 diabetes. J\u00a0Am Soc Nephrol. 2013;24(2):302\u20138.","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"1425_CR48","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1007\/BF00281993","volume":"28","author":"K Borch-Johnsen","year":"1985","unstructured":"Borch-Johnsen K, Andersen PK, Deckert T. The effect of proteinuria on relative mortality in type 1 (insulin-dependent) diabetes mellitus. Diabetologia. 1985;28(8):590\u20136.","journal-title":"Diabetologia"},{"issue":"7","key":"1425_CR49","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.2337\/db08-1543","volume":"58","author":"PH Groop","year":"2009","unstructured":"Groop PH, Thomas MC, Moran JL, et al. The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. Diabetes. 2009;58(7):1651\u20138.","journal-title":"Diabetes"},{"issue":"6","key":"1425_CR50","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1681\/ASN.2012080870","volume":"24","author":"M Tonelli","year":"2013","unstructured":"Tonelli M, Muntner P, Lloyd A, et al. Association between LDL-C and risk of myocardial infarction in CKD. J\u00a0Am Soc Nephrol. 2013;24(6):979\u201386.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"1425_CR51","doi-asserted-by":"crossref","first-page":"263","DOI":"10.7326\/0003-4819-157-4-201208210-00007","volume":"157","author":"SC Palmer","year":"2012","unstructured":"Palmer SC, Craig JC, Navaneethan SD, Tonelli M, Pellegrini F, Strippoli GF. Benefits and harms of statin therapy for persons with chronic kidney disease: a\u00a0systematic review and meta-analysis. Ann Intern Med. 2012;157(4):263\u201375.","journal-title":"Ann Intern Med"},{"issue":"8","key":"1425_CR52","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1681\/ASN.2013090965","volume":"25","author":"R Haynes","year":"2014","unstructured":"Haynes R, Lewis D, Emberson J, et\u00a0al. Effects of lowering LDL cholesterol on progression of kidney disease. J\u00a0Am Soc Nephrol. 2014;25(8):1825\u201333.","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"1425_CR53","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1038\/ki.2014.31","volume":"85","author":"C Wanner","year":"2014","unstructured":"Wanner C, Tonelli M, Kidney Disease. Improving Global Outcomes Lipid Guideline Development Work Group M. KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int. 2014;85(6):1303\u20139.","journal-title":"Kidney Int"},{"key":"1425_CR54","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.kint.2017.12.011","volume":"93","author":"PP Toth","year":"2018","unstructured":"Toth PP, Dwyer JP, Cannon CP, et\u00a0al. Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease. Kidney Int. 2018;93:1397. \n                    https:\/\/doi.org\/10.1016\/j.kint.2017.12.011\n                    \n                  .","journal-title":"Kidney Int"},{"issue":"8","key":"1425_CR55","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1097\/TP.0b013e3182861945","volume":"95","author":"C Margreiter","year":"2013","unstructured":"Margreiter C, Resch T, Oberhuber R, et al. Combined pancreas-kidney transplantation for patients with end-stage nephropathy caused by type-2 diabetes mellitus. Transplantation. 2013;95(8):1030\u20136.","journal-title":"Transplantation"},{"key":"1425_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir2018.04.008","author":"FC Prischl","year":"2018","unstructured":"Prischl FC, Wanner C. Renal outcomes of antidiabetic treatment options for type 2 diabetes\u2014a\u00a0proposed MARE definition. Kidney Int Rep. 2018; \n                    https:\/\/doi.org\/10.1016\/j.ekir2018.04.008\n                    \n                  .","journal-title":"Kidney Int Rep"},{"issue":"18","key":"1425_CR57","first-page":"1801","volume":"375","author":"C Wanner","year":"2016","unstructured":"Wanner C, Inzucchi SE, Zinman B. Empagliflozin and progression of kidney disease in type 2 diabetes. N\u00a0Engl J Med. 2016;375(18):1801\u20132.","journal-title":"N Engl J Med"},{"key":"1425_CR58","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfx350","author":"CCJ Dekkers","year":"2018","unstructured":"Dekkers CCJ, Wheeler DC, Sjostrom CD, Stefansson BV, Cain V, Heerspink HJL. Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b\u20134 chronic kidney disease. Nephrol Dial Transplant. 2018; \n                    https:\/\/doi.org\/10.1093\/ndt\/gfx350\n                    \n                  .","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"1425_CR59","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1161\/CIRCULATIONAHA.117.028268","volume":"137","author":"C Wanner","year":"2018","unstructured":"Wanner C, Lachin JM, Inzucchi SE, et\u00a0al. Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease. Circulation. 2018;137(2):119\u201329.","journal-title":"Circulation"},{"issue":"7","key":"1425_CR60","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, et\u00a0al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N\u00a0Engl J Med. 2017;377(7):644\u201357.","journal-title":"N Engl J Med"},{"key":"1425_CR61","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812389","author":"SD Wiviott","year":"2018","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and Cardiovascular Outcomes in Type\u00a02 Diabetes. NEJM. 2018. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1812389","journal-title":"NEJM"},{"issue":"4","key":"1425_CR62","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N\u00a0Engl J Med. 2016;375(4):311\u201322.","journal-title":"N Engl J Med"},{"issue":"19","key":"1425_CR63","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, et\u00a0al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N\u00a0Engl J Med. 2016;375(19):1834\u201344.","journal-title":"N Engl J Med"},{"issue":"12","key":"1425_CR64","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1007\/s00108-012-3203-6","volume":"53","author":"G Schernthaner","year":"2012","unstructured":"Schernthaner G, Schernthaner GH. Current treatment of type 2 diabetes. Internist (Berl). 2012;53(12):1399\u2013410.","journal-title":"Internist (Berl)"},{"issue":"5","key":"1425_CR65","doi-asserted-by":"crossref","first-page":"948","DOI":"10.3390\/jcm4050948","volume":"4","author":"M Alsahli","year":"2015","unstructured":"Alsahli M, Gerich JE. Hypoglycemia in patients with diabetes and renal disease. J\u00a0Clin Med. 2015;4(5):948\u201364.","journal-title":"J Clin Med"},{"issue":"5","key":"1425_CR66","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2165\/00003088-199630050-00003","volume":"30","author":"AJ Scheen","year":"1996","unstructured":"Scheen AJ. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 1996;30(5):359\u201371.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"1425_CR67","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1159\/000323739","volume":"118","author":"HJ Nye","year":"2011","unstructured":"Nye HJ, Herrington WG. Metformin: the safest hypoglycaemic agent in chronic kidney disease? Nephron Clin Pract. 2011;118(4):380\u20133.","journal-title":"Nephron Clin Pract"},{"issue":"4","key":"1425_CR68","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/j.1440-1797.2010.01328.x","volume":"15","author":"HL Pilmore","year":"2010","unstructured":"Pilmore HL. Review: metformin: potential benefits and use in chronic kidney disease. Nephrology (Carlton). 2010;15(4):412\u20138.","journal-title":"Nephrology (Carlton)"},{"issue":"24","key":"1425_CR69","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1001\/jama.2014.15298","volume":"312","author":"SE Inzucchi","year":"2014","unstructured":"Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK. Metformin in patients with type 2 diabetes and kidney disease: a\u00a0systematic review. JAMA. 2014;312(24):2668\u201375.","journal-title":"JAMA"},{"issue":"3","key":"1425_CR70","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2337\/dc17-2231","volume":"41","author":"JD Lalau","year":"2018","unstructured":"Lalau JD, Kajbaf F, Bennis Y, Hurtel-Lemaire AS, Belpaire F, De Broe ME. Metformin treatment in patients with type 2 diabetes and chronic kidney disease stages 3A, 3B, or 4. Diabetes Care. 2018;41(3):547\u201353.","journal-title":"Diabetes Care"},{"issue":"Suppl 2","key":"1425_CR71","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1093\/ndt\/gfv100","volume":"30","author":"Guideline development group","year":"2015","unstructured":"Guideline development group. Clinical Practice Guideline on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR \u300845\u202fmL\/min). Nephrol Dial Transplant. 2015;30(Suppl 2):ii1\u2013142.","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"1425_CR72","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.diabres.2015.07.002","volume":"110","author":"SP Chan","year":"2015","unstructured":"Chan SP, Colagiuri S. Systematic review and meta-analysis of the efficacy and hypoglycemic safety of gliclazide versus other insulinotropic agents. Diabetes Res Clin Pract. 2015;110(1):75\u201381.","journal-title":"Diabetes Res Clin Pract"},{"issue":"11","key":"1425_CR73","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1111\/j.1463-1326.2008.00928.x","volume":"10","author":"J Tayek","year":"2008","unstructured":"Tayek J. SUR receptor activity vs. incidence of hypoglycaemia and cardiovascular mortality with sulphonylurea therapy for diabetics. Diabetes Obes Metab. 2008;10(11):1128\u20139. author reply 9\u201330.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"1425_CR74","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1464-5491.2004.01426.x","volume":"22","author":"BH Charbonnel","year":"2005","unstructured":"Charbonnel BH, Matthews DR, Schernthaner G, Hanefeld M, Brunetti P, Group QS. A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a\u00a0randomized, double-blind, parallel-group comparison trial. Diabet Med. 2005;22(4):399\u2013405.","journal-title":"Diabet Med"},{"issue":"1","key":"1425_CR75","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2337\/diacare.27.1.141","volume":"27","author":"M Hanefeld","year":"2004","unstructured":"Hanefeld M, Brunetti P, Schernthaner GH, Matthews DR, Charbonnel BH, Group QS. One-year glycemic control with a\u00a0sulfonylurea plus pioglitazone versus a\u00a0sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care. 2004;27(1):141\u20137.","journal-title":"Diabetes Care"},{"issue":"2","key":"1425_CR76","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/dmrr.478","volume":"21","author":"DR Matthews","year":"2005","unstructured":"Matthews DR, Charbonnel BH, Hanefeld M, Brunetti P, Schernthaner G. Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a\u00a0randomized, comparative study. Diabetes Metab Res Rev. 2005;21(2):167\u201374.","journal-title":"Diabetes Metab Res Rev"},{"issue":"12","key":"1425_CR77","doi-asserted-by":"crossref","first-page":"6068","DOI":"10.1210\/jc.2003-030861","volume":"89","author":"G Schernthaner","year":"2004","unstructured":"Schernthaner G, Matthews DR, Charbonnel B, Hanefeld M, Brunetti P, Quartet Study G. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a\u00a0double-blind, randomized trial. J\u00a0Clin Endocrinol Metab. 2004;89(12):6068\u201376.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1425_CR78","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1001\/jama.2015.7996","volume":"314","author":"JD Lewis","year":"2015","unstructured":"Lewis JD, Habel LA, Quesenberry CP, et\u00a0al. Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes. JAMA. 2015;314(3):265\u201377.","journal-title":"JAMA"},{"issue":"1","key":"1425_CR79","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/dom.13049","volume":"20","author":"EM Garry","year":"2018","unstructured":"Garry EM, Buse JB, Lund JL, Pate V, Sturmer T. Comparative safety of pioglitazone versus clinically meaningful treatment alternatives concerning the risk of bladder cancer in older US adults with type 2 diabetes. Diabetes Obes Metab. 2018;20(1):129\u201340.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"1425_CR80","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1001\/jama.2013.8141","volume":"310","author":"M Mitka","year":"2013","unstructured":"Mitka M. Panel recommends easing restrictions on rosiglitazone despite concerns about cardiovascular safety. JAMA. 2013;310(3):246\u20137.","journal-title":"JAMA"},{"issue":"16","key":"1425_CR81","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMp1010788","volume":"363","author":"J Woodcock","year":"2010","unstructured":"Woodcock J, Sharfstein JM, Hamburg M. Regulatory action on rosiglitazone by the U.S. Food and Drug Administration. N\u00a0Engl J Med. 2010;363(16):1489\u201391.","journal-title":"N Engl J Med"},{"key":"1425_CR82","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.bone.2014.08.010","volume":"68","author":"ZN Zhu","year":"2014","unstructured":"Zhu ZN, Jiang YF, Ding T. Risk of fracture with thiazolidinediones: an updated meta-analysis of randomized clinical trials. Bone. 2014;68:115\u201323.","journal-title":"Bone"},{"issue":"11","key":"1425_CR83","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1210\/jc.2015-1215","volume":"100","author":"AV Schwartz","year":"2015","unstructured":"Schwartz AV, Chen H, Ambrosius WT, et\u00a0al. Effects of TZD use and discontinuation on fracture rates in ACCORD Bone study. J\u00a0Clin Endocrinol Metab. 2015;100(11):4059\u201366.","journal-title":"J Clin Endocrinol Metab"},{"key":"1425_CR84","volume-title":"Safety of liraglutide vs. placebo in patients with type 2 diabetes and CKD in the LEADER trial","author":"JMO Mann","year":"2017","unstructured":"Mann JMO, Raz I, Frimer-Larsen H, von Scholten B, Idorn T, Poulter N, LEADER Trial Investigators. Safety of liraglutide vs. placebo in patients with type 2 diabetes and CKD in the LEADER trial. New Orleans: American Society of Nephrology Kidney Week; 2017."},{"issue":"10","key":"1425_CR85","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.2337\/dc14-0865","volume":"37","author":"A Avogaro","year":"2014","unstructured":"Avogaro A, Fadini GP. The effects of dipeptidyl peptidase-4 inhibition on microvascular diabetes complications. Diabetes Care. 2014;37(10):2884\u201394.","journal-title":"Diabetes Care"},{"issue":"6","key":"1425_CR86","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.2337\/db14-0366","volume":"63","author":"U Panchapakesan","year":"2014","unstructured":"Panchapakesan U, Pollock CA. DPP-4 inhibitors-renoprotection in diabetic nephropathy? Diabetes. 2014;63(6):1829\u201330.","journal-title":"Diabetes"},{"issue":"5","key":"1425_CR87","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1177\/1479164114542802","volume":"11","author":"G Schernthaner","year":"2014","unstructured":"Schernthaner G, Mogensen CE, Schernthaner GH. The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system. Diab Vasc Dis Res. 2014;11(5):306\u201323.","journal-title":"Diab Vasc Dis Res"},{"issue":"19","key":"1425_CR88","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1093\/eurheartj\/ehv728","volume":"37","author":"D Fitchett","year":"2016","unstructured":"Fitchett D, Zinman B, Wanner C, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(R) trial. Eur Heart\u00a0J. 2016;37(19):1526. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehv728\n                    \n                  .","journal-title":"Eur Heart J"},{"issue":"22","key":"1425_CR89","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et\u00a0al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N\u00a0Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med"},{"issue":"5","key":"1425_CR90","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","volume":"311","author":"PA James","year":"2014","unstructured":"James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507\u201320.","journal-title":"JAMA"},{"issue":"3","key":"1425_CR91","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/ki.2012.425","volume":"83","author":"DC Wheeler","year":"2013","unstructured":"Wheeler DC, Becker GJ. Summary of KDIGO guideline. What do we really know about management of blood pressure in patients with chronic kidney disease? Kidney Int. 2013;83(3):377\u201383.","journal-title":"Kidney Int"},{"issue":"3","key":"1425_CR92","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1093\/ndt\/gft321","volume":"29","author":"F Verbeke","year":"2014","unstructured":"Verbeke F, Lindley E, Van Bortel L, et al. A European Renal Best Practice (ERBP) position statement on the Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guideline for the management of blood pressure in non-dialysis-dependent chronic kidney disease: an endorsement with some caveats for real-life application. Nephrol Dial Transplant. 2014;29(3):490\u20136.","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"1425_CR93","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1053\/j.ajkd.2013.03.018","volume":"62","author":"SJ Taler","year":"2013","unstructured":"Taler SJ, Agarwal R, Bakris GL, et\u00a0al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD. Am J Kidney Dis. 2013;62(2):201\u201313.","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"1425_CR94","doi-asserted-by":"crossref","first-page":"884","DOI":"10.7326\/0003-4819-144-12-200606200-00005","volume":"144","author":"FH Messerli","year":"2006","unstructured":"Messerli FH, Mancia G, Conti CR, et\u00a0al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med. 2006;144(12):884\u201393.","journal-title":"Ann Intern Med"},{"issue":"1","key":"1425_CR95","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1001\/archinternmed.2011.619","volume":"172","author":"CA Peralta","year":"2012","unstructured":"Peralta CA, Norris KC, Li S, et al. Blood pressure components and end-stage renal disease in persons with chronic kidney disease: the Kidney Early Evaluation Program (KEEP). Arch Intern Med. 2012;172(1):41\u20137.","journal-title":"Arch Intern Med"},{"issue":"4","key":"1425_CR96","doi-asserted-by":"crossref","first-page":"233","DOI":"10.7326\/0003-4819-159-4-201308200-00004","volume":"159","author":"CP Kovesdy","year":"2013","unstructured":"Kovesdy CP, Bleyer AJ, Molnar MZ, et\u00a0al. Blood pressure and mortality in U.S. veterans with chronic kidney disease: a\u00a0cohort study. Ann Intern Med. 2013;159(4):233\u201342.","journal-title":"Ann Intern Med"},{"issue":"20","key":"1425_CR97","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","volume":"329","author":"EJ Lewis","year":"1993","unstructured":"Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N\u00a0Engl J Med. 1993;329(20):1456\u201362.","journal-title":"N Engl J Med"},{"issue":"12","key":"1425_CR98","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","volume":"345","author":"EJ Lewis","year":"2001","unstructured":"Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N\u00a0Engl J Med. 2001;345(12):851\u201360.","journal-title":"N Engl J Med"},{"key":"1425_CR99","doi-asserted-by":"crossref","first-page":"i438","DOI":"10.1136\/bmj.i438","volume":"352","author":"S Bangalore","year":"2016","unstructured":"Bangalore S, Fakheri R, Toklu B, Messerli FH. Diabetes mellitus as a\u00a0compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials. BMJ. 2016;352:i438.","journal-title":"BMJ"},{"issue":"7","key":"1425_CR100","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1097\/01.hjh.0000431740.32696.cc","volume":"31","author":"G Mancia","year":"2013","unstructured":"Mancia G, Fagard R, Narkiewicz K, et\u00a0al. 2013 ESH\/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J\u00a0Hypertens. 2013;31(7):1281\u2013357.","journal-title":"J Hypertens"},{"issue":"20","key":"1425_CR101","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","volume":"369","author":"LF Fried","year":"2013","unstructured":"Fried LF, Emanuele N, Zhang JH, et\u00a0al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N\u00a0Engl J Med. 2013;369(20):1892\u2013903.","journal-title":"N Engl J Med"},{"issue":"23","key":"1425_CR102","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","volume":"367","author":"HH Parving","year":"2012","unstructured":"Parving HH, Brenner BM, McMurray JJ, et\u00a0al. Cardiorenal end points in a\u00a0trial of aliskiren for type 2 diabetes. N\u00a0Engl J Med. 2012;367(23):2204\u201313.","journal-title":"N Engl J Med"},{"issue":"9638","key":"1425_CR103","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","volume":"372","author":"JF Mann","year":"2008","unstructured":"Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a\u00a0multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372(9638):547\u201353.","journal-title":"Lancet"},{"issue":"9721","key":"1425_CR104","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S0140-6736(09)62100-0","volume":"375","author":"GL Bakris","year":"2010","unstructured":"Bakris GL, Sarafidis PA, Weir MR, et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a\u00a0prespecified secondary analysis of a\u00a0randomised controlled trial. Lancet. 2010;375(9721):1173\u201381.","journal-title":"Lancet"},{"issue":"23","key":"1425_CR105","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa0806182","volume":"359","author":"K Jamerson","year":"2008","unstructured":"Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N\u00a0Engl J Med. 2008;359(23):2417\u201328.","journal-title":"N Engl J Med"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-018-1425-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00508-018-1425-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-018-1425-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,10]],"date-time":"2020-04-10T23:18:59Z","timestamp":1586560739000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00508-018-1425-x"}},"subtitle":["Positionspapier der \u00d6sterreichischen Diabetes Gesellschaft und der \u00d6sterreichischen Gesellschaft f\u00fcr Nephrologie","Position paper of the Austrian Diabetes Association and the Austrian Society for Nephrology"],"short-title":[],"issued":{"date-parts":[[2019,4,12]]},"references-count":105,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["1425"],"URL":"https:\/\/doi.org\/10.1007\/s00508-018-1425-x","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,12]]},"assertion":[{"value":"12 April 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.\u00a0Sourij hat von folgenden Unternehmen, die auch f\u00f6rdernde Mitglieder der \u00d6DG sind, Forschungsunterst\u00fctzungen und\/oder Honorare erhalten: Amgen, AstraZeneca, Boehringer-Ingelheim, Eli Lilly, Merck Sharp & Dohme, Novo Nordisk, Sanofi-Aventis, Takeda. R.\u00a0Edlinger hat Honorare f\u00fcr Vortr\u00e4ge in den letzten Jahren von folgenden Firmen erhalten: AstraZeneca, Boehringer Ingelheim, Merck Sharp & Dohme, Takeda, Novartis und Sanofi-Aventis. Betreff der Leitlinien hat R.\u00a0Edlinger keine unmittelbaren Interessenkonflikte anzugeben. F.C.\u00a0Prischl hat (w\u00e4hrend seiner beruflichen Laufbahn) Honorare f\u00fcr Vortr\u00e4ge, Reiseunterst\u00fctzungen oder Honorare als Mitglied von Advisory Boards von AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Janssen-Cilag, Novartis, Roche, Takeda erhalten. S.\u00a0Kaser hat von folgenden Unternehmen, die auch f\u00f6rdernde Mitglieder der \u00d6DG sind, Forschungsunterst\u00fctzungen und\/oder Honorare erhalten: AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Novartis, Novo Nordisk, Sanofi-Aventis, Servier, Takeda. S.\u00a0Horn hat von folgenden Unternehmen Vortragshonorare erhalten: Servier, Novartis, Boehringer-Ingelheim.\u00a0Betreff der Leitlinien hat S.\u00a0Horn keine unmittelbaren Interessenkonflikte anzugeben. B.\u00a0Paulweber hat in den letzten Jahren von folgenden Unternehmen Forschungsunterst\u00fctzungen und\/oder Honorare f\u00fcr Vortrags- und\/oder Beratungst\u00e4tigkeiten erhalten: Abbott, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Bayer, Eli Lilly, Merck Sharp & Dohme, Mylan, Novartis, Novo Nordisk, Pfizer, Sanofi-Aventis, Takeda. Betreff der Leitlinien besteht kein Interessenkonflikt. A.\u00a0Kautzky-Willer hat von folgenden Unternehmen, die auch f\u00f6rdernde Mitglieder der \u00d6DG sind, Forschungsunterst\u00fctzungen\/Honorare erhalten: Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Sanofi-Aventis. M.\u00a0S\u00e4emann hat von folgenden Unternehmen Forschungsunterst\u00fctzungen und\/oder Honorare erhalten: Amgen, Astellas, Boehringer-Ingelheim, Chiesi, Novartis, Otsuka, Vifor. M.\u00a0Clodi hat von folgenden Unternehmen, die auch f\u00f6rdernde Mitglieder der \u00d6DG sind, Forschungsunterst\u00fctzungen und\/oder Honorare erhalten: AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Novartis, Novo Nordisk, Sanofi-Aventis, Servier, Takeda. M.\u00a0Auinger, R.\u00a0Prager, G.\u00a0Schernthaner, G.\u00a0Mayer, R.\u00a0Oberbauer und A.R.\u00a0Rosenkranz geben an, dass kein Interessenkonflikt besteht.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}